Laser therapy with cemiplimab for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This study tests a treatment that uses a laser to heat and destroy the recurring brain tumor during a procedure called LITT, followed by an immunotherapy drug called cemiplimab that helps your immune system fight the cancer. This might help people whose glioblastoma has come back after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of brain tumor called glioblastoma (grade 4) that has returned after initial treatment
- You are at least 18 years old
- You are generally able to care for yourself (Karnofsky score of 60% or higher)
- You are eligible for the laser procedure (LITT) based on the size and location of your tumor as determined by your surgeon
- You have recovered from side effects of previous treatments and are not on certain other cancer therapies right now
- You have not had certain prior treatments like immunotherapy drugs or bevacizumab within the recommended time frames
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines laser heat therapy (LITT) with the chemotherapy drug lomustine (CCNU) for people whose glioblastoma has returned. It aims to see if the combination is safe and effective.
This trial studies a two-step treatment for newly diagnosed high-grade glioma: first laser treatment (LITT) to target the tumor, followed by a shorter, more focused course of radiation. It may help shrink or control the tumor while limiting treatment time.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.